[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].
Yudong Peng, Kai Meng, Hongquan Guan, L Leng, Ruirui Zhu, Boyuan Wang, Meian He, Longxian Cheng, Kai Huang, Qiutang Zeng
Abstract
COVID-19 patients combined with CVD are associated with a higher risk of mortality. Critical patients are characterized with lower lymphocyte counts. Higher BMI are more often seen in critical patients and non-survivor. ACEI/ARB use does not affect the morbidity and mortality of COVID-19 combined with CVD. Aggravating causes of death include fulminant inflammation, lactic acid accumulation and thrombotic events.
Topics & Concepts
MedicineProcalcitoninInternal medicineGastroenterologySepsisRenal replacement therapyLipid profileRenal functionCholesterolCOVID-19 Clinical Research StudiesCOVID-19 and healthcare impactsLong-Term Effects of COVID-19